Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments.
Lago C, Federico A, Leva G, Mack NL, Schwalm B, Ballabio C, Gianesello M, Abballe L, Giovannoni I, Reddel S, Rossi S, Leone N, Carai A, Mastronuzzi A, Bisio A, Soldano A, Quintarelli C, Locatelli F, Kool M, Miele E, Tiberi L. Lago C, et al. Among authors: quintarelli c. EMBO Mol Med. 2023 Dec 7;15(12):e18199. doi: 10.15252/emmm.202318199. Epub 2023 Nov 30. EMBO Mol Med. 2023. PMID: 38037472 Free PMC article.
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Del Baldo G, Del Bufalo F, Pinacchio C, Carai A, Quintarelli C, De Angelis B, Merli P, Cacchione A, Locatelli F, Mastronuzzi A. Del Baldo G, et al. Among authors: quintarelli c. Front Immunol. 2023 Mar 21;14:1142597. doi: 10.3389/fimmu.2023.1142597. eCollection 2023. Front Immunol. 2023. PMID: 37025994 Free PMC article. Review.
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, Reddel S, Iaffaldano L, Pezzella M, Di Cecca S, Sinibaldi M, Ottaviani A, Quadraccia MC, Aurigemma M, Sarcinelli A, Ciccone R, Abbaszadeh Z, Ceccarelli M, De Vito R, Lodi MC, Cefalo MG, Mastronuzzi A, De Angelis B, Locatelli F, Quintarelli C. Manni S, et al. Among authors: quintarelli c. Nat Commun. 2023 Jun 9;14(1):3423. doi: 10.1038/s41467-023-38723-y. Nat Commun. 2023. PMID: 37296093 Free PMC article.
Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
Carbone ML, Capone A, Guercio M, Reddel S, Silvestris DA, Lulli D, Ramondino C, Peluso D, Quintarelli C, Volpe E, Failla CM. Carbone ML, et al. Among authors: quintarelli c. Front Immunol. 2023 Aug 23;14:1197630. doi: 10.3389/fimmu.2023.1197630. eCollection 2023. Front Immunol. 2023. PMID: 37680638 Free PMC article.
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
Pezzella M, Quintarelli C, Quadraccia MC, Sarcinelli A, Manni S, Iaffaldano L, Ottaviani A, Ciccone R, Camera A, D'Amore ML, Di Cecca S, Sinibaldi M, Guercio M, Aurigemma M, De Falco P, Fustaino V, Rota R, Pomella S, Cassandri M, Di Giannatale A, Agrati C, Bordoni V, Guarracino F, Massa M, Del Baldo G, Becilli M, Milano GM, Del Bufalo F, Locatelli F, De Angelis B. Pezzella M, et al. Among authors: quintarelli c. J Hematol Oncol. 2024 Dec 18;17(1):127. doi: 10.1186/s13045-024-01641-7. J Hematol Oncol. 2024. PMID: 39695851 Free PMC article.
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study.
Mastronuzzi A, Carsetti R, De Ioris MA, Agrati C, Del Baldo G, Russo C, Cefalo MG, Merli P, Perno CF, dell'Anna VA, Serra A, Bordoni V, Piano Mortari E, Marcellini V, Albano C, Linardos G, Costabile V, Sinibaldi M, Guercio M, di Cecca S, Quintarelli C, Locatelli F. Mastronuzzi A, et al. Among authors: quintarelli c. Heliyon. 2024 Jul 11;10(14):e34503. doi: 10.1016/j.heliyon.2024.e34503. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39713186 Free PMC article.
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. Del Bufalo F, et al. Among authors: quintarelli c. N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. N Engl J Med. 2023. PMID: 37018492
110 results